Hyperaldosteronism as a common cause of resistant hypertension

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 233-247

  Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

aldosterone; chlorthalidone; hypertension specialist; spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMILORIDE; ANTIHYPERTENSIVE AGENT; BUMETANIDE; CHLORTALIDONE; EPLERENONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; SPIRONOLACTONE;

ADIPOCYTE; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERALDOSTERONISM; LIFESTYLE MODIFICATION; MEDICAL SPECIALIST; OBESITY; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; RESISTANT HYPERTENSION; RISK ASSESSMENT; SEX DIFFERENCE; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 84873034035     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-042711-135929     Document Type: Article

References (44)

1. Calhoun DA, Jones D, Textor S, et al. 2008. American Heart Association scientific statement on resistant hypertension: diagnosis, evaluation, and treatment. Hypertension 51:1403-19
2. Persell SD. 2011. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 57:1076-80
3. Egan BM, Zhao Y, Axon RN, et al. 2011. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988-2008. Circulation 124:1046-58
4. de la Sierra A, Segura J, Banegas JR, et al. 2011. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57:898-902
5. Gupta AK, Nasothimiou EG, Chane CL, et al., on behalf of the ASCOT investigators. 2011. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J. Hypertens. 29:2004-13
6. American Heart Association. 2011. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123:e18-209
7. Cushman WC, Ford CE, Einhorn PT, et al. for the ALLHAT Collaborative Research Group. 2008. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. 10:751-60
8. Pimenta E, Gaddam KK, Oparil S, et al. 2009. Effects of dietary sodium restriction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 54:475-81
9. Daugherty SL, Powers JD, Magid DJ, et al. 2012. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125:1635-42
10. Caro JJ, Speckman JL, Salas M, et al. 1999. Effect of initial drug choice on persistencewith antihypertensive therapy: the importance of actual practice data. Can. Med. Assoc. J. 160:41-46
11. Ceral J, Habrdova V, Vorisek V, et al. 2011. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens. Res. 34:87-90
12. Bunker J, Callister W, Chang C-L, et al. 2011. How common is true resistant hypertension? J. Hum. Hypertens. 25:137-40
13. Muxfeldt ES, Fiszman R, de Souza F, et al. 2012. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension 59:384-89
14. Logan AG, Perlikowski SM, Mente A, et al. 2001. High prevalence of unrecognized sleep apnea in drugresistant hypertension. J. Hypertens. 19:2271-77
15. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. 2007. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131:453-59
16. Alajmi M, Mulgrew AT, Fox J, et al. 2007. Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. Lung 185:67-72
17. MoL, He QY. 2007. Effect of long-term continuous positive airway pressure ventilation on blood pressure in patients with obstructive sleep apnea hypopnea syndrome: a meta-analysis of clinical trials. Zhonghua Zue Zhi 87:1177-80
18. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. 2007. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome. Arch. Intern. Med. 167:757-65
19. Vasan RS, Evans JC, Larson MG, et al. 2004. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 351:33-41
20. Conn JW. 1955. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 45:3-17
21. Fishman LM, Küchel O, Liddle GW, et al. 1968. Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA 205:497-502
22. KaplanNM.1967. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann. Intern. Med. 66:1079-90
23. Gordon RD, StowasserM, Tunny TJ, et al. 1994. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21:315-18
24. Mosso L, Carvajal C, GonzálezA, et al. 2003. Primary aldosteronism and hypertensive disease. Hypertension 2:161-65
25. Calhoun DA, Nishizaka MK, Zaman MA, et al. 2002. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 40:892-96
26. Gallay BJ, Ahmad S, Xu L, et al. 2001. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis. 37:699-705
27. Eide IK, Torjesen PA, Drolsum A, et al. 2004. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens. 22:2217-26
28. Štrauch B, Zelinka T, Hampf M, et al. 2003. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J. Hum. Hypertens. 17:349-52
29. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. 2008. Resistant hypertension characterized by increased aldosterone levels and persistent intravascular volume expansion. Arch. Intern. Med. 168:1159-64
30. Mulè G, Nardi E, Cusimano P, et al. 2008. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with metabolic syndrome. Am. J. Hypertens. 21:1055-61
31. Rossi GP, Belfiore A, Bernini G, et al. 2008. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J. Clin. Endocrinol. Metab. 93:2566-71
32. Weiland F, Verspohl EJ. 2009. Local formation of angiotensin peptides with paracrine activity by adipocytes. J. Pept. Sci. 15:767-76
33. Kershaw EE, Flier JS. 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89:2548-56
34. Briones AM, Nguyen Ninh Cat A, Callera GE, et al. 2012. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59:1069-78
35. Dall'Asta C, Vedani P, Manunta P, et al. 2009. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr.Metab. Cardiovasc. Dis. 19:110-14
36. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. 2003. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. USA 100:14211-16
37. Nishizaka MK, Zaman MA, Calhoun DA. 2003. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16:925-30
38. Chapman N, Dobson J, Wilson S, et al. 2007. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49:839-45
39. Calhoun DA, WhiteWB. 2008. Effectiveness of the selective aldosterone antagonist eplerenone in treating resistant hypertension. J. Am. Soc. Hypertens. 2:462-68
40. Saha C, Eckert GJ, Ambrosius WT, et al. 2005. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46:481-87
41. Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, et al. 2010. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J. Hypertens. 28:2329-35
42. ErnstME, Carter BL, GoerdtCJ, et al. 2006. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47:352-58
43. Bansal N, Tendler BE, White WB, et al. 2003. Blood pressure control in the hypertension clinic. Am. J. Hypertens. 16:878-80
44. AcelajadoMC, Pisoni R, Dudenbostel T, et al. 2012. Refractory hypertension: definition, prevalence and patient characteristics. J. Clin. Hypertens. 14:7-12